Clinical Response of Rheumatoid Arthritis-Associated Pulmonary Fibrosis to Tumor Necrosis Factor-α Inhibition
- 30 September 2002
- Vol. 122 (3), 1093-1096
- https://doi.org/10.1378/chest.122.3.1093
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Growth factors in idiopathic pulmonary fibrosis: relative rolesRespiratory Research, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Idiopathic Pulmonary Fibrosis: Diagnosis and TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Idiopathic Nonspecific Interstitial Pneumonia: Prognostic Significance of Cellular and Fibrosing PatternsThe American Journal of Surgical Pathology, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis.JCI Insight, 1995
- Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in miceEuropean Respiratory Journal, 1994
- Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosisNature, 1990
- Pulmonary fibrosis in rheumatoid arthritis: A review of clinical features and therapySeminars in Arthritis and Rheumatism, 1987